Melguizo, C., Prados, J., González, B., Ortiz, R., Concha, A., Alvarez, P. J., . . . Aránega, A. (2012). MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. BioMed Central.
استشهاد بنمط شيكاغوMelguizo, Consolación, et al. MGMT Promoter Methylation Status and MGMT and CD133 Immunohistochemical Expression As Prognostic Markers in Glioblastoma Patients Treated With Temozolomide Plus Radiotherapy. BioMed Central, 2012.
MLA استشهادMelguizo, Consolación, et al. MGMT Promoter Methylation Status and MGMT and CD133 Immunohistochemical Expression As Prognostic Markers in Glioblastoma Patients Treated With Temozolomide Plus Radiotherapy. BioMed Central, 2012.